Reuters logo
BRIEF-Neurovive says NVP015 program reaches milestone
November 30, 2017 / 7:37 AM / 16 days ago

BRIEF-Neurovive says NVP015 program reaches milestone

Nov 30 (Reuters) - Neurovive Pharmaceutical Ab:

* NEUROVIVE‘S GENETIC MITOCHONDRIAL DISEASE PROGRAM NVP015 REACHES SIGNIFICANT MILESTONE

* SAYS ‍MOLECULES IN ITS NVP015 PROGRAM HAVE DEMONSTRATED POSITIVE EFFECTS IN EXPERIMENTAL MODELS OF GENETIC MITOCHONDRIAL DISEASE AND THAT A LEAD COMPOUND HAS BEEN SELECTED​

* SAYS ‍LEAD WAS SELECTED BASED ON TOLERABILITY, PLASMA STABILITY AND ORGAN DELIVERY, SPECIFICALLY TO BRAIN, AND WILL NOW BE TAKEN INTO FURTHER IN VIVO EXPERIMENTAL EFFICACY STUDIES AND PRECLINICAL DEVELOPMENT​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below